NSC-620621(NSC-620621) - _专利_临床

概要

基本信息

药物类型

小分子化药

别名

Antineoplaston AS2-1、Astugenal

靶点-

作用机制-

治疗领域

肿瘤神经系统疾病其他疾病

在研适应症-

非在研适应症

中枢神经系统肿瘤弥漫内生性脑桥神经胶质瘤神经鞘瘤+ [1]

原研机构

Burzynski Research Institute, Inc.

在研机构-

非在研机构

Burzynski Research Institute, Inc.

最高研发阶段暂停临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

63

项与 NSC-620621 相关的临床试验

NCT02864888 / Not yet recruiting临床3期IIT

A Controlled, Study of the Effect of Combination Antineoplaston Therapy [Atengenal (A10) and Astugenal (AS2-1)] on the QT/QTc Interval In Subjects With Newly Diagnosed Diffuse, Intrinsic, Brainstem Glioma

The primary objective of this protocol study is to investigate the effect of Antineoplaston therapy on the QT/QTc interval in study subjects age 3 to 21 years with newly-diagnosed, diffuse, intrinsic brainstem glioma. This investigation is to be conducted in parallel with a phase 3 efficacy and safety study of combination Antineoplaston therapy + radiation vs. radiation alone (BRI-BT-52).

开始日期2027-06-01

申办/合作机构

Burzynski Research Institute, Inc.

NCT02887040 / Not yet recruiting临床3期IIT

A Randomized Phase 3 Study of Combination Antineoplaston Therapy [Antineoplastons A10 (Atengenal) and AS2-1 (Astugenal)] Plus Radiation Therapy vs. Radiation Therapy Only in Subjects With Newly Diagnosed Diffuse, Intrinsic, Brainstem Glioma

Patients ≥ 3 years of age with newly-diagnosed, diffuse, intrinsic pontine glioma will be enrolled in this study. However, the primary objectives of this study are to 1) compare overall survival, the time from randomization to death from any cause, for study subjects 3-21 years of age with newly-diagnosed, diffuse, intrinsic pontine glioma who receive Antineoplaston therapy (Atengenal + Astugenal) + radiation therapy vs. radiation therapy alone and 2) describe the toxicity profile (all subjects) for Antineoplaston therapy + radiation therapy vs. radiation therapy alone.
A secondary objective is to compare progression-free survival for study subjects 3-21 years of age with newly-diagnosed, diffuse, intrinsic pontine glioma treated with Antineoplaston therapy + radiation therapy vs. radiation therapy alone.

开始日期2025-06-01

申办/合作机构

Burzynski Research Institute, Inc.

NCT04542681 / Withdrawn临床1期IIT

A Phase I, Single-Blind, Placebo-Controlled Study Evaluating the Cardiovascular Properties of MANP in African Americans With Hypertension

Evaluate the cardiovascular properties of MANP in AA with Hypertension

开始日期2018-05-01

申办/合作机构

Mayo Clinic

100 项与 NSC-620621 相关的临床结果

登录后查看更多信息

100 项与 NSC-620621 相关的转化医学

登录后查看更多信息

100 项与 NSC-620621 相关的专利（医药）

登录后查看更多信息

17

项与 NSC-620621 相关的文献（医药）

2014-01-01·Oncology Reports3区 · 医学

Demethylation effect of the antineoplaston AS2-1 on genes in colon cancer cells

3区 · 医学

Article

作者: Yutaka Ogata ; Keiko Matono ; Yoshito Akagi ; Kazuo Shirouzu ; Masataka Ushijima ; Hideaki Tsuda

Antineoplastons are naturally occurring peptides and amino acid derivatives found in human blood and urine. antineoplastons have been shown to control neoplastic growth. In the present study, we investigated demethylation effect of the antineoplaston AS2-1 (a mixture of phenylacetylglutamine and phenylacetate in the ratio of 1:4) on various genes in colon cancer cells. An HpaII-MspI methylation microarray was used to investigate the methylation status of 51 genes at the promoter region in HCT116 and KM12SM human colon cancer cells before and after treatment of AS2-1. The expression of protein and mRNA of the demethylated genes by AS2-1 in HCT116 cells was evaluated. In 19 of the 34 methylated genes in HCT116 and in 7 of the 8 methylated genes in KM12SM, the methylation status was downregulated after treatment with 2 mg/ml of AS2-1 for 24 h. AS2-1 dramatically downregulated the methylation status of p15 and ESR1 in HCT116 cells and of MTHFR and MUC2 in KM12SM cells. Both mRNA and protein expression of p15 increased in a dose- and time-dependent manner after treatment with AS2-1. The antineoplaston AS2-1 may normalize the hypermethylation status at the promoter region in various genes including tumor suppressor genes, resulting in activation of the transcription and translation in colon cancer.

2009-04-01·Bioorganic & Medicinal Chemistry3区 · 医学

Novel aminopeptidase N inhibitors derived from antineoplaston AS2–5 (Part II)

3区 · 医学

Article

作者: Jifeng Wu ; Wenfang Xu ; Yonggang Li ; Xun Li ; Qiang Wang ; Yazhou Wang

As our ongoing work, a series of peptidomimetic L-iso-glutamine derivatives derived from antineoplaston AS2-5 scaffold were prepared and their APN/CD13 and MMP-2 inhibitory activities were evaluated hereby. The results displayed that these compounds exhibited selective inhibition against APN as compared with MMP-2, with IC(50) values in micromole range. Compounds A1 and A2 showed comparable APN inhibitory activities than the positive control bestatin.

2003-06-01·Surgery Today4区 · 医学

Long-Term Survival Following Treatment with Antineoplastons for Colon Cancer with Unresectable Multiple Liver Metastases: Report of a Case

4区 · 医学

Article

作者: Keiko Matono ; Yoshito Akagi ; Hideaki Tsuda ; Yasumi Araki ; Tsutomu Kumabe ; Michio Sata ; Hiroshi Hara ; Kazuo Shirouzu ; Hideki Saitsu ; Yutaka Ogata

We report a case of survival for nearly 8 years after treatment of unresectable multiple liver metastases from colon cancer, using microwave ablation and the nontoxic antitumor agent, the antineoplastons. A 72-year-old man diagnosed with adenocarcinoma of the ascending colon and 14 bilateral liver metastases underwent a right hemicolectomy combined with microwave ablation of six metastatic liver tumors. We also decided to give antineoplastons to inhibit metastatic tumor growth and recurrence. Antineoplaston A10 was given intravenously, followed by oral antineoplaston AS2-1. Computed tomography scans done 1 and 4 years after the initial diagnosis showed recurrent tumors in S(4) and S(7), respectively. The patient underwent a second and a third microwave ablation of the recurrent tumors, and has survived for nearly 8 years without suffering any serious adverse effects. He is currently free from cancer. This case report demonstrates the potential effectiveness of the nontoxic antitumor agent, the antineoplastons, for controlling liver metastases from colon cancer.

100 项与 NSC-620621 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
弥漫内生性脑桥神经胶质瘤	临床2期	美国	Burzynski Research Institute, Inc.	2016-04-13
中枢神经系统肿瘤	临床2期	美国	Burzynski Research Institute, Inc.	1999-03-01
神经鞘瘤	临床2期	美国	Burzynski Research Institute, Inc.	1999-03-01
神经纤维瘤	临床2期	美国	Burzynski Research Institute, Inc.	1999-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00003487 (CTgov)	临床2期	食管腺癌	8	Atengenal+Astugenal	憲範範範窪艱衊觸憲艱(遞襯壓淵積膚壓淵窪齋) = 鏇網糧廠鬱夢衊糧餘範構窪觸繭觸鬱獵憲構衊 (蓋餘鑰醖艱觸願鬱艱餘, 鹽餘鑰憲積鹽廠艱繭淵 ~ 範鹽繭鑰襯鹽蓋鏇夢蓋) 更多	-	2021-05-14
NCT00003508 (CTgov)	临床2期	恶性间皮瘤	8	Atengenal+Astugenal	蓋構夢憲醖簾築餘鑰憲(淵鹹餘壓遞夢蓋遞遞遞) = 築齋鏇觸鏇築廠顧鬱憲顧製餘鑰醖顧鬱鏇餘艱 (網憲鬱糧選築齋窪鹽構, 蓋壓獵廠製選築鹹顧範 ~ 鑰憲衊夢夢構糧網繭製) 更多	-	2021-02-21
NCT00003511 (CTgov)	临床2期	多发性骨髓瘤	5	Atengenal+Astugenal	壓鹽鏇艱網範餘鏇遞鑰(餘鏇齋艱廠遞襯繭構衊) = 構鬱齋艱鹹鹹範顧獵艱顧構遞獵積襯觸壓齋醖 (鏇壓遞網鹽簾顧夢獵壓, 範積衊選窪憲構鹹艱醖 ~ 遞選獵襯廠淵齋醖選鬱) 更多	-	2021-01-28
NCT00003509 (CTgov)	临床2期	黑色素瘤	13	Atengenal+Astugenal	(醖衊襯膚餘衊築遞窪夢) = 繭憲願窪醖憲願糧廠觸醖繭鬱遞觸遞鑰遞衊選 (築鑰齋簾製衊鹹簾築鏇, 齋範糧鑰糧糧獵衊衊衊 ~ 製構蓋選繭製壓餘製簾) 更多	-	2020-12-19
NCT00003498 (CTgov)	临床2期	非霍奇金淋巴瘤	5	Atengenal+Astugenal	積衊艱齋觸壓鏇構壓範(遞顧鑰憲顧獵鹹壓鹹膚) = 鹹鑰積壓遞遞廠遞構餘醖築艱選襯鏇構壓製構 (願廠獵觸襯鏇範餘夢簾, 獵餘繭製壓鑰觸鬱衊蓋 ~ 齋顧繭蓋衊鑰觸艱膚製) 更多	-	2020-12-19
NCT00003526 (CTgov)	临床2期	腺癌 \| 原发部位不明恶性肿瘤	8	Atengenal+Astugenal	(製網蓋廠憲鹹築齋遞膚) = 積鬱憲餘窪繭衊壓製壓膚蓋選積蓋壓廠鹹築顧 (築醖範壓遞衊構顧構獵, 醖遞蓋範顧鬱簾餘繭遞 ~ 繭鑰製艱範願構顧夢廠) 更多	-	2020-12-17
NCT00003531 (CTgov)	临床2期	胰腺腺癌	15	Atengenal+Astugenal	鑰繭鬱獵壓鹹選構廠糧(範窪鹹獵廠鑰築夢糧醖) = 憲憲簾膚廠醖遞鬱襯積繭餘鏇製鏇憲觸艱糧窪 (簾鹽醖鹹願壓餘顧鑰齋, 鏇築淵夢鏇廠壓糧簾衊 ~ 網構鑰繭齋積齋憲蓋鏇) 更多	-	2020-12-17
NCT00003492 (CTgov)	临床2期	未分化大细胞肺癌	9	Atengenal+Astugenal	夢憲艱簾遞願憲憲壓衊(憲繭艱選衊觸艱醖齋蓋) = 糧艱鬱襯窪蓋觸網願襯鹽襯夢夢簾遞願夢網淵 (鏇築衊積獵糧蓋鹹鹹餘, 鹽鹽範遞餘鏇憲憲齋簾 ~ 積鑰觸顧艱遞積衊餘獵) 更多	-	2020-12-16
NCT00003499 (CTgov)	临床2期	低级别 B 细胞非霍奇金淋巴瘤	31	Atengenal+Astugenal	(鑰網鹹蓋蓋鹹襯積獵齋) = 齋顧願獵鏇夢夢範遞鏇積鑰遞廠築簾積鹹鹹窪 (繭襯襯繭醖襯構醖蓋繭, 鑰鹹網憲窪觸鹽簾廠壓 ~ 淵鬱糧憲鏇襯憲窪製遞) 更多	-	2019-04-16
NCT00003453 (CTgov)	临床2期	肾上腺皮质癌	6	Atengenal+Astugenal	(鹹顧蓋襯鹹壓鬱積遞鏇) = 築觸蓋襯憲網顧鑰醖簾鹽壓鏇鏇餘構構鹽製膚 (壓廠憲鹹鬱選艱淵遞顧, 艱獵構夢鑰襯鏇齋鏇夢 ~ 壓襯餘繭鏇簾蓋壓淵廠) 更多	-	2018-05-09